Wegovy launches in the US at a list price above $1,300 a month

Novo Nordisk began selling Wegovy (semaglutide) in the United States in June 2021, shortly after the FDA approved it on June 4, 2021 for adults with obesity ^[2]. The launch list price was above $1,300 for a month's supply, reported as $1,349.02 per package — a number that stayed unchanged for years. That exact figure is not itemized in the company materials reviewed here; Novo Nordisk's current patient site points visitors to a separate "Understanding List Price" explainer instead of posting the number on its pricing page ^[1].

List price is the sticker price a manufacturer sets before rebates, insurer negotiations and discounts. Almost no one pays it if they have coverage. But in 2021, insurance for obesity medicines was uncommon, so many people who wanted Wegovy were quoted something close to that full amount at the pharmacy counter. How many plans covered the drug at launch is not documented in the sources available for this story.

How the price picture changed

The cash-pay landscape looks very different now. On March 5, 2025, Novo Nordisk introduced NovoCare Pharmacy and dropped the cost of all doses of Wegovy to $499 per month for people paying without insurance ^[2]. On February 24, 2026, the company announced what it called a significant reduction in the US list price for Wegovy, Ozempic and Rybelsus — all semaglutide products ^[2]. On March 31, 2026, it launched a multi-month subscription program for Wegovy that it said offers savings of up to $1,200 a year ^[2].

As of the company's current pricing page, self-pay patients new to the Wegovy savings offer or NovoCare Pharmacy pay $199 a month for the 0.25 mg and 0.5 mg injection pens for the first two monthly fills, an offer running through December 31, 2026 ^[1]. After that, the listed self-pay price is $349 a month for the 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg pens, and $399 a month for Wegovy HD 7.2 mg ^[1]. One month is defined as one box of four pens ^[1].

The oral version is priced by dose: $149 a month for Wegovy pill 1.5 mg, $199 for 4 mg, and $299 for both 9 mg and 25 mg, with one month defined as a bottle of 30 tablets ^[1]. People with commercial insurance may pay as little as $25 a month through a savings card, subject to a maximum savings of $100 a month; government beneficiaries, such as people on Medicare or Medicaid, are excluded ^[1]. Novo Nordisk says it can modify or cancel these programs at any time ^[1].

Wegovy's approved uses have also widened well beyond the 2021 obesity indication. It was approved for teens 12 and older in December 2022, for cardiovascular risk reduction in March 2024, and granted accelerated approval for noncirrhotic MASH with moderate to advanced liver fibrosis in August 2025 ^[2]. A once-daily Wegovy tablet was approved December 22, 2025, and a higher-dose Wegovy HD injection on March 19, 2026 ^[2].

Why it matters for patients

The 2021 list price is the baseline that explains a lot of what followed: years of coverage fights, compounded copies, and a steady march of manufacturer discount programs. For someone comparing costs today, the practical takeaway is that three very different numbers exist — the list price, the cash self-pay price through the manufacturer's own pharmacy, and the out-of-pocket amount after commercial insurance and a savings card.

Those numbers do not move together. A list price cut does not automatically lower a copay, and a savings card with a $100 monthly cap does not help everyone equally ^[1]. People on Medicare or Medicaid are excluded from the $25 commercial offer entirely ^[1]. Whether the February 2026 list price cut changes what any specific plan charges is not spelled out in these sources.

What happens next

The $199-a-month introductory self-pay offer for new Wegovy pen patients is set to run through December 31, 2026, after which the listed prices rise to $349 or $399 a month depending on the pen ^[1]. Because Novo Nordisk reserves the right to change or end these programs at any time, current pricing should be confirmed directly before assuming it will hold ^[1].